Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vacuolating cytotoxin A (VacA) is a potent pore-forming toxin and a primary virulence factor secreted by Helicobacter pylori (UniProt: P55981). It is produced as a 140 kDa precursor that is processed into an 88 kDa mature toxin, which further dissociates into p33 and p58 subunits (PubMed: 15932242). VacA exerts its effects by forming anion-selective channels in the host cell plasma membrane and endosomal membranes, leading to the characteristic formation of large cytoplasmic vacuoles (PubMed: 26854168). Additionally, VacA targets mitochondria to induce cytochrome c release and apoptosis, and it suppresses the immune system by interfering with T-lymphocyte activation and proliferation (PubMed: 11544351). Given its critical role in the development of gastric ulcers and gastric cancer, VacA is a key target for therapeutic intervention and vaccine development (PubMed: 28438503).
Inhibition of toxin binding to host cell receptors, neutralization of toxin-induced vacuolation, and blockade of pore-forming activity in host membranes.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vacuolating cytotoxin A (VacA) (VacA).